Allyson J. Ocean

Allyson J. Ocean

Auto-generated profile, based on publicly available information

Allyson J. Ocean

New York-Presbyterian Hospital 1 Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NewYork

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Annals of Oncology
Verified
Journal Article
Open access
ABA. Bardia
A. Bardia
WMW.A. Messersmith
W.A. Messersmith
EKE.A. Kio
E.A. Kio
JBJ.D. Berlin
J.D. Berlin
LVL. Vahdat
L. Vahdat
AOA.J. Ocean
A.J. Ocean
Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with advanced epithelial cancers. This report summarizes the safety data from the overall safety population (OSP) and efficacy data, including additional disease cohorts not published previously. Patients with refractory metastatic epithelial cancers received intravenous SG (8, 10, 12, or 18 mg/kg) on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity. Endpoints for the OSP included safety and pharmacokinetic parameters with investigator-evaluated objective response rate (ORR per RECIST 1.1), duration of response, clinical benefit rate, progression-free survival, and overall survival evaluated for cohorts (n > 10 patients) of small-cell lung, colorectal, esophageal, endometrial, pancreatic ductal adenocarcinoma, and castrate-resistant prostate cancer. In the OSP (n = 495, median age 61 years, 68% female; UGT1A1∗28 homozygous, n = 46; 9.3%), 41 (8.3%) permanently discontinued treatment due to adverse events (AEs). Most common treatment-related AEs were nausea (62.6%), diarrhea (56.2%), fatigue (48.3%), alopecia (40.4%), and neutropenia (57.8%). Most common treatment-related serious AEs (n = 75; 15.2%) were febrile neutropenia (4.0%) and diarrhea (2.8%). Grade ≥3 neutropenia and febrile neutropenia occurred in 42.4% and 5.3% of patients, respectively. Neutropenia (all grades) was numerically more frequent in UGT1A1∗28 homozygotes (28/46; 60.9%) than heterozygotes (69/180; 38.3%) or UGT1A1∗1 wild type (59/177; 33.3%). There was one treatment-related death due to an AE of aspiration pneumonia. Partial responses were seen in endometrial cancer (4/18, 22.2% ORR) and small-cell lung cancer (11/62, 17.7% ORR), and one castrate-resistant prostate cancer patient had a complete response (n = 1/11; 9.1% ORR). SG demonstrated a toxicity profile consistent with previous published reports. Efficacy was seen in several cancer cohorts, which validates Trop-2 as a broad target in solid tumors.

30 May 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
AOAllyson J. Ocean
Allyson J. Ocean
ASAlexander N. Starodub
Alexander N. Starodub
ABAditya Bardia
Aditya Bardia
LVLinda T. Vahdat
Linda T. Vahdat
SISteven J. Isakoff
Steven J. Isakoff
DGDavid M. Goldenberg
David M. Goldenberg

8 May 2012 in Cancer
Verified
Journal Article
Open access
PDF file
AOAllyson J. Ocean
Allyson J. Ocean
KPKenneth L. Pennington
Kenneth L. Pennington
MGMichael J. Guarino
Michael J. Guarino
ASArif Sheikh
Arif Sheikh
TBTanios Bekaii‐Saab
Tanios Bekaii‐Saab
DGDavid M. Goldenberg
David M. Goldenberg
BACKGROUND: It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of radioimmunotherapy that determined the maximum tolerated dose of single‐dose yttrium‐90‐labeled hPAM4 (90Y‐hPAM4) and produced objective responses in patients with advanced pancreatic ductal carcinoma, the authors studied fractionated radioimmunotherapy combined with low‐dose gemcitabine in this disease.METHODS: Thirty‐eight previously untreated patients (33 patients with stage IV disease and 5 patients with stage III disease) received gemcitabine 200 mg/m2 weekly for 4 weeks with 90Y‐hPAM4 given weekly in Weeks 2, 3, and 4 (cycle 1), and the same cycle was repeated in 13 patients (cycles 2‐4). In the first part of the study, 19 patients received escalating weekly 90Y doses of 6.5 mCi/m2, 9.0 mCi/m2, 12.0 mCi/m2, and 15.0 mCi/m2. In the second portion, 19 additional patients received weekly doses of 9.0 mCi/m2 or 12.0 mCi/m2.RESULTS: Grade 3/4 thrombocytopenia or neutropenia (according to version 3.0 of the National Cancer Institute's Common Terminology Criteria for Adverse Events) developed in 28 of 38 patients after cycle 1 and in all retreated patients; no grade >3 nonhematologic toxicities occurred. Fractionated dosing of cycle 1 allowed almost twice the radiation dose compared with single‐dose radioimmunotherapy. The maximum tolerated dose of 90Y‐hPAM4 was 12.0 mCi/m2 weekly for 3 weeks for cycle 1, with ≤9.0 mCi/m2 weekly for 3 weeks for subsequent cycles, and that dose will be used in future trials. Six patients (16%) had partial responses according to computed tomography‐based Response Evaluation Criteria in Solid Tumors, and 16 patients (42%) had stabilization as their best response (58% disease control). The median overall survival was 7.7 months for all 38 patients, including 11.8 months for those who received repeated cycles (46% [6 of 13 patients] ≥1 year), with improved efficacy at the higher radioimmunotherapy doses.CONCLUSIONS: Fractionated radioimmunotherapy with 90Y‐hPAM4 and low‐dose gemcitabine demonstrated promising therapeutic activity and manageable myelosuppression in patients with advanced pancreatic ductal carcinoma. Cancer 2012. © 2012 American Cancer Society.

1 August 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
KKKelsey A. Klute
Kelsey A. Klute
JBJulianna Brouwer
Julianna Brouwer
MJMinaxi Jhawer
Minaxi Jhawer
HSHayley Sachs
Hayley Sachs
AGAnatasia Gangadin
Anatasia Gangadin
MSManish A Shah
Manish A Shah

10 March 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SGSANJAY GOEL
SANJAY GOEL
AOAllyson J. Ocean
Allyson J. Ocean
RPRuwan Y. Parakrama
Ruwan Y. Parakrama
MGMohammad H. Ghalib
Mohammad H. Ghalib
ICImran Chaudhary
Imran Chaudhary
RMRadhashree Maitra
Radhashree Maitra
KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is synergistic with irinotecan. A dose escalation trial of FOLFIRI/bevacizumab [irinotecan (150–180 mg/m2) and pelareorep (1 × 1010 TCID50–3 × 1010 TCID50)] was implemented in adult patients with oxaliplatin refractory/intolerant, KRAS-mutant mCRC. Pelareorep was administered intravenously over 1 hour on days 1–5 every 4 weeks. Additional studies included pharmacokinetics, tumor morphology, and immune responses. Among FOLFIRI-naïve patients, the highest dose of FOLFIRI/bevacizumab (180 mg/m2 irinotecan) and pelareorep (3 × 1010 TCID50) was well tolerated, without a dose-limiting toxicity. At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively. Toxicities included myelosuppression, fatigue, and diarrhea. Transmission electron microscopy revealed viral factories (viral collections forming vesicular structures), at various stages of development. Immunogold staining against viral capsid σ-1 protein demonstrated viral “homing” in the tumor cells. The nucleus displayed sufficient euchromatin regions suggestive of active transcription. Flow cytometry revealed rapid dendritic cell maturation (48 hours) with subsequent activation of cytotoxic T cells (7 days). The combination of pelareorep with FOLFIRI/bevacizumab is safe. The PFS and OS data are encouraging and deserve further exploration. Pelareorep leads to a clear recurrent immune stimulatory response with cytotoxic T-cell activation, and homes and replicates in the tumor.

2 June 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
BNBabak B. Navi
Babak B. Navi
CZCenai Zhang
Cenai Zhang
CSCarla P. Sherman
Carla P. Sherman
RGRichard Genova
Richard Genova
NLNatalie M. LeMoss
Natalie M. LeMoss
LDLisa M. DeAngelis
Lisa M. DeAngelis